EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma

Andrée-Anne Pelland iD, Mathilde Dumas, Émilie Lemieux-Blanchard, Richard LeBlanc iD, Julie Côté, Jean-Samuel Boudreault iD, Dominic Duquette, Rayan Kaedbey, Marc Lalancette, Frédéric Larose, Anna Nikonova iD, Michel Pavic iD und 5 weitere

Current Oncology · 2025

DOI: 10.3390/curroncol32040238 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2025. Verfasst von Andrée-Anne Pelland und 16 weiteren Autor:innen. Beteiligte Einrichtung: BC Cancer, Vancouver, BC V5Z 4E6, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, T-Lymphocytes. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Myeloma Canada Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the past few years, a new promising therapy, called bispecific T-cell engager (TCE), has been developed and is now available in many countries for patients with relapsed or refractory multiple myeloma. T-cell engagers are associated with sustained efficacy and progression-free survival benefits in patients with heavily treated myeloma. However, complications such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections complicate their administration, particularly in remote centers. This review discusses the key requirements for delivering TCEs therapies, focusing on outpatient delivery. We also outline the primary acute and chronic complications of TCE therapy and their management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, BispecificT-LymphocytesHumansOutpatients

Stichwörter der Autor:innen

bispecific antibodiesmultiple myelomatargeted immunotherapytoxicity

Substanzen

Antibodies, Bispecific

Autor:innen und Institutionen

  • BC Cancer, Vancouver, BC V5Z 4E6, Canada.
  • Centre Hospitalier Universitaire de Québec (CHU), Québec, QC G1V 0E8, Canada.
  • Hôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, Canada.
  • Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC H2X 3E4, Canada.
  • Hôpital du Sacré-Cœur de Montréal, Montréal, QC H4J 1C5, Canada.
  • Jewish General Hospital, Montréal, QC H3T 1E2, Canada.

ORCID-Profile: Andrée-Anne Pelland, Richard LeBlanc, Jean-Samuel Boudreault, Anna Nikonova, Michel Pavic, Jean Roy, Jean-Sébastien Claveau

Förderung

  • Myeloma Canada Grant

Zitieren

APA

Pelland, A. A., Dumas, M., Lemieux-Blanchard, É., LeBlanc, R., Côté, J., Boudreault, J. S., Duquette, D., Kaedbey, R., Lalancette, M., Larose, F., Nikonova, A., Pavic, M., Shamy, A., Roy, J., Sebag, M., Trudel, S., & Claveau, J. S. (2025). Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma. Current Oncology. https://doi.org/10.3390/curroncol32040238

Vancouver

Pelland AA, Dumas M, Lemieux-Blanchard É, LeBlanc R, Côté J, Boudreault JS, et al. Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma. Current Oncology. 2025. doi:10.3390/curroncol32040238

BibTeX
@article{Pelland2025,
  author = {Pelland, Andrée-Anne and Dumas, Mathilde and Lemieux-Blanchard, Émilie and LeBlanc, Richard and Côté, Julie and Boudreault, Jean-Samuel and Duquette, Dominic and Kaedbey, Rayan and Lalancette, Marc and Larose, Frédéric and Nikonova, Anna and Pavic, Michel and Shamy, April and Roy, Jean and Sebag, Michael and Trudel, Sabrina and Claveau, Jean-Sébastien},
  title = {Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32040238}
}
Kostenlos starten →